Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis

Autor: Nancy Tricoche, Christina A. Bulman, Judy A. Sakanari, Shabnam Jawahar, Sara Lustigman
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Nematoda
Physiology
RC955-962
Molting
Bioinformatics
Onchocerciasis
Pharmacokinetic Analysis
chemistry.chemical_compound
Ivermectin
Medical Conditions
Elimination Half-Life Calculation
Depsipeptides
Arctic medicine. Tropical medicine
Medicine and Health Sciences
Public and Occupational Health
media_common
biology
Pharmaceutics
Eukaryota
Moxidectin
Viewpoints
Infectious Diseases
Helminth Infections
Larva
Onchocerca
Macrolides
Public aspects of medicine
RA1-1270
medicine.drug
Neglected Tropical Diseases
Drug
Drug Research and Development
Drug Administration
media_common.quotation_subject
Pharmacotherapy
Drug Therapy
Helminths
parasitic diseases
medicine
Parasitic Diseases
Animals
Humans
Pharmacology
business.industry
Prophylaxis
Public Health
Environmental and Occupational Health
Organisms
Biology and Life Sciences
medicine.disease
biology.organism_classification
Tropical Diseases
Onchocerca volvulus
Invertebrates
Clinical trial
Regimen
Pharmacologic Analysis
Filaricides
chemistry
Leukocytes
Mononuclear
Benzimidazoles
Preventive Medicine
business
Physiological Processes
Zoology
Zdroj: PLoS Neglected Tropical Diseases, Vol 15, Iss 2, p e0009064 (2021)
PLoS Neglected Tropical Diseases
ISSN: 1935-2735
1935-2727
Popis: Several issues have been identified with the current programs for the elimination of onchocerciasis that target only transmission by using mass drug administration (MDA) of the drug ivermectin. Alternative and/or complementary treatment regimens as part of a more comprehensive strategy to eliminate onchocerciasis are needed. We posit that the addition of “prophylactic” drugs or therapeutic drugs that can be utilized in a prophylactic strategy to the toolbox of present microfilaricidal drugs and/or future macrofilaricidal treatment regimens will not only improve the chances of meeting the elimination goals but may hasten the time to elimination and also will support achieving a sustained elimination of onchocerciasis. These “prophylactic” drugs will target the infective third- (L3) and fourth-stage (L4) larvae of Onchocerca volvulus and consequently prevent the establishment of new infections not only in uninfected individuals but also in already infected individuals and thus reduce the overall adult worm burden and transmission. Importantly, an effective prophylactic treatment regimen can utilize drugs that are already part of the onchocerciasis elimination program (ivermectin), those being considered for MDA (moxidectin), and/or the potential macrofilaricidal drugs (oxfendazole and emodepside) currently under clinical development. Prophylaxis of onchocerciasis is not a new concept. We present new data showing that these drugs can inhibit L3 molting and/or inhibit motility of L4 at IC50 and IC90 that are covered by the concentration of these drugs in plasma based on the corresponding pharmacological profiles obtained in human clinical trials when these drugs were tested using various doses for the therapeutic treatments of various helminth infections.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje